

- 76 -

BEST AVAILABLE COPY

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12N 15/00, 7/00, 5/00 C12P 21/00, 19/30, A61K 39/12 A61K 37/00		A1	(11) International Publication Number: WO 90/13641 (43) International Publication Date: 15 November 1990 (15.11.90)
(21) International Application Number: PCT/US90/02656 (22) International Filing Date: 10 May 1990 (10.05.90)			(72) Inventors; and (75) Inventors/Applicants (for US only) : GILBOA, Eli [US/US]; 147 Boulder Ridge Road, Scarsdale, NY 10583 (US). SULLENGER, Bruce [US/US]; 420 East 70th Street, Apt. 5M, New York, NY 10021 (US).
(30) Priority data: 354,171 10 May 1989 (10.05.89) US (60) Parent Application or Grant (63) Related by Continuation US Filed on 354,171 (CIP) 10 May 1989 (10.05.89)			(74) Agent: WHITE, John, P.; Cooper & Dunham, 30 Rockefeller Plaza, New York, NY 10112 (US). (81) Designated States: AT (European patent), BE (European + patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US.
(71) Applicant (for all designated States except US): SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH [US/US]; 1275 York Avenue, New York, NY 10021 (US).			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: STABLY TRANSFORMED EUKARYOTIC CELLS COMPRISING A FOREIGN TRANSCRIBABLE DNA UNDER THE CONTROL OF A POL III PROMOTER			
(57) Abstract <p>This invention provides a stably transformed eukaryotic cell comprising a pol III promoter and a foreign transcribable DNA, the foreign transcribable DNA being under the control of the pol III promoter. This invention also provides retroviral vector which comprises a chimeric t-RNA introduced into the 3' long terminal repeat (LTR) of the retroviral vector.</p>			

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT Austria	ES Spain	MC Monaco
AU Australia	FI Finland	MG Madagascar
BB Barbados	FR France	ML Mali
BE Belgium	GA Gabon	MR Mauritania
BF Burkina Fasso	GB United Kingdom	MW Malawi
BG Bulgaria	GR Greece	NL Netherlands
BJ Benin	HU Hungary	NO Norway
BR Brazil	IT Italy	RO Romania
CA Canada	JP Japan	SD Sudan
CF Central African Republic	KP Democratic People's Republic of Korca	SE Sweden
CG Congo	KR Republic of Korca	SN Senegal
CH Switzerland	LI Liechtenstein	SU Soviet Union
CM Cameroon	LK Sri Lanka	TD Chad
DE Germany, Federal Republic of	LU Luxembourg	TG Togo
DK Denmark		US United States of America

1

Stably Transformed Eucaryotic Cells Comprising foreign
transcribable DNA under the control of a pol III Promoter

5 This application is a continuation-in-part of United States
application serial number 354,171, filed May 10, 1989, the
contents of which are hereby incorporated by reference into
the present disclosure.

10 Throughout this application various publications are
referred by numbers within parenthesis. Full citations for
these publications may be found at the end of the
specification immediately preceding the claims. The
disclosures of these publications, in their entireties, are
15 hereby incorporated by reference into this application in
order to more fully describe the state of the art to which
this invention pertains.

Background of the Invention

20 The potential of inhibiting the expression of specific genes
in live cells was recently demonstrated using a technique
called antisense RNA (or DNA) inhibition ("antisense
inhibition"). This technique is based on blocking the flow
25 of genetic information from DNA via RNA to protein, by the
introduction into the cells, of a complementary sequence (in
the form of a single stranded RNA or DNA molecule called
antisense RNA or DNA) to a portion of the target RNA.
Through nucleotide base pairing, a duplex is formed which
blocks the expression of the function or the gene encoded in
30 the RNA transcript through one of several possible
mechanisms: degradation of the duplex; inhibition of
translation; or other (11, 22, 37).

-2-

Regulation of gene expression via antisense RNA was first recognized as a naturally occurring mechanism in prokaryotes (11). The potential of using complementary sequences to inhibit specific gene functions was demonstrated by 5 Paterson, et al. (28) who used complementary nucleic acids to inhibit the translation of specific mRNA species in vitro. However, it was the pioneering work of Zamecnik and Stephenson (38) who first demonstrated the experimental inhibition of the expression of specific genes in live cells 10 via antisense RNA. This inhibition was accomplished by the use of a synthetic oligonucleotide, complementary to a portion of the Rous sarcoma virus (RSV), to inhibit viral replication in cultured cells.

15 Inhibition of specific genes using antisense DNA templates (also called antisense genes) was first demonstrated by Pestka (29) and Coleman, et al. (5) in bacteria and later by Izant and Weintraub (16) in eucaryotic cells. This was an 20 important development since antisense DNA templates ("antisense templates") are capable of synthesizing antisense RNA on a continual basis when introduced into the eucaryotic cell and therefore have the potential to exert a long lasting effect on the cell and its progeny.

25 It is important to distinguish between transient antisense and stable antisense inhibition protocols because each of these protocol achieve different objectives and employ different technologies. Transient antisense inhibition, as 30 the name implies, results in the creation of a temporary state of inhibition in the cell. The use of antisense oligonucleotides, microinjection of antisense RNA or

-3-

transient DNA transfection protocols, and use of SV40 based vectors are examples of protocols by which transient antisense inhibition is accomplished (22).

5

On the other hand, stable antisense RNA inhibition involves the permanent genetic alteration of the cell, achieved by the introduction of antisense templates which persist in the cell and its progeny, by synthesizing antisense RNA on a continual basis. The stable introduction of antisense templates into the cell can be accomplished by using any of several gene transfer techniques. Such techniques for the alteration of cells may involve, but are not limited to: (i) physical methods such as CaPO_4 mediated DNA transfection; (ii) electroporation; or (iii) use of viral vectors such as retroviral vectors. These methods can produce stably altered cells by the insertion of the antisense DNA into the cell chromosome or, via use of viral vectors, such as bovine papilloma virus or Epstein-Barr virus, introduction of the antisense templates will persist in the cell as freely replicating episomes (22).

stable antisense inhibition

25 The stable form of antisense RNA inhibition has an enduring effect which creates a constant state of gene inhibition in the host cell and its progeny. It therefore provides a distinct advantage over the use of the transient protocol.

30 A stable antisense inhibition protocol requires the design of a DNA template which upon transfer to the cell is capable of synthesizing adequate levels of antisense RNA to inhibit

-4-

- the expression of the target gene. To accomplish this objective, the DNA template must encode an efficient transcriptional unit. A eucaryotic transcriptional unit 5 comprises: (i) a promoter to initiate RNA transcription; (ii) the template of the RNA transcript; and (iii) a third region signalling RNA transcription termination. Three distinct RNA polymerases are known to exists in eucaryotic 10 cells: (a) RNA polymerase I (pol I) which transcribes ribosomal genes; (b) RNA polymerase II (pol II) which is responsible for the expression of the protein coding cellular genes; and (c) RNA polymerase III (pol III) which transcribes the 5S and t-RNA genes.
- 15 A stable antisense inhibition protocol also requires an excess of RNA transcripts because antisense RNA inhibition requires the formation of stable duplexes between the antisense RNA and the target RNA. Indeed, several studies 20 have shown that an apparent 30-100 fold excess of antisense RNA is required to obtain a 10-20 fold reduction in gene expression (16, 17, 20 and 26). However, other studies have shown that in some experimental systems a more moderate 25 excess of 3-10 fold may lead to an observable inhibition (4, 21, 25 and reviewed in reference 22).
- 25 Therefore, the effectiveness of stable and transient 30 antisense RNA inhibition is determined by the ratio of antisense RNA to sense RNA, which in turn is determined by the efficiency of antisense RNA synthesis from the corresponding DNA template.

The development of effective stable antisense inhibition

-5-

protocols in eucaryotic cells is hampered by the lack of efficient antisense templates that are capable of synthesizing sufficient levels of antisense RNA. The nature 5 of the promoter and its polymerase are of pivotal importance in the design of efficient antisense templates which will produce high levels of antisense RNA in cells stably transduced with the antisense template. So far, pol II based promoters have been used exclusively to generate 10 antisense transcripts in stable antisense inhibition protocols (22).

Pol III based transcriptional units

15 In an attempt to improve antisense RNA synthesis using stable gene transfer protocols, the use of pol III promoters to drive the expression of antisense RNA can be considered. The underlying rationale for the use of pol III promoters is that they can generate substantially higher levels of RNA 20 transcripts in cells as compared to pol II promoters. For example, it is estimated that in a eucaryotic cell there are about 6×10^7 t-RNA molecules and 7×10^5 mRNA molecules, i.e., about 100 fold more pol III transcripts of this class than total pol II transcripts (39). Since there are about 25 100 active t-RNA genes per cell, each t-RNA gene will generate on the average RNA transcripts equal in number to total pol II transcripts. Since an abundant pol II gene transcript represents about 1% of total mRNA while an average pol II transcript represents about 0.01% of total 30 mRNA, a t-RNA (pol III) based transcriptional unit may be able to generate 100 fold to 10,000 fold more RNA than a pol II based transcriptional unit.

-6-

Several reports have described the use of pol III promoters to express RNA in eucaryotic cells. Lewis and Manley (23) and Sisodia (34) have fused the Adenovirus VA-1 promoter to 5 various DNA sequences (the herpes TK gene globin and tubulin) and used transfection protocols to transfer the resulting DNA constructs into cultured cells which resulted in transient synthesis of RNA in the transduced cell. De la Pena and Zasloff (6) have expressed a t-RNA-Herpes TK fusion 10 DNA construct upon microinjection into frog oocytes. Jennings and Molloy have constructed an antisense RNA template by fusing the VA-1 gene promoter to a DNA fragment derived from SV40 based vector which also resulted in transient expression of antisense RNA and limited inhibition 15 of the target gene (18).

Common to the above cited studies is that the pol III based DNA templates were introduced into cells using a gene transfer procedure which led only to transient synthesis of 20 pol III driven RNA transcripts in the cell. Furthermore, since the number of active DNA templates present in the transiently transduced cells cannot be determined, the efficiency of pol III based transcription was not and could not have been determined.

25 It is the objective of this invention to design improved DNA templates which can be stably transferred into the eucaryotic cell and which are capable of synthesizing large quantities of antisense RNA, RNA, or gene product.

30

-7-

Summary of the Invention

This invention provides a stably transformed eucaryotic cell
5 comprising a pol III promoter and a foreign transcribable DNA, the foreign transcribable DNA being under the control of the pol III promoter.

This invention also provides a retroviral vector which
10 comprises a chimeric t-RNA introduced into the 3' long terminal repeat (LTR) of the retroviral vector.

15

20

25

30

35

-8-

Description of the Figures

5 Figure 1: Structure of a prototype t-RNA, a human t-RNA^{i_{met}} derivative and a chimeric t-RNA gene.

10 Figure 1A shows the structure of a prototype t-RNA gene. A t-RNA gene is 85-95 base pairs long. Two regions designated A and B encode the promoter which directs the initiation of RNA transcription to generate the primary transcript. Termination of transcription is specified by a run of four or more T residues on the sense strand. Arrow indicates that transcription usually terminate after the third T. The primary t-RNA transcript is further processed to remove sequences both from the 5' end and the 3' end as shown, to generate the mature t-RNA transcript. (Additional modifications including addition of CCA and base modifications are not shown). For additional information see the review by Gaiduscheck, 1988 (9).

20 Figure 1B shows the structure of a human t-RNA^{i_{met}} derivative 3-5. 3-5 was derived from a cloned human t-RNA gene by deleting 19bp from the 3' end of the gene (1). The truncated gene can be transcribed if a termination signal is provided, however, no processing of the 3' end of the primary transcript takes place.

30 Figure 1C shows a chimeric t-RNA gene. A foreign sequence is fused to the 3' end of t-RNA^{i_{met}} 3-5 and a termination signal also is added. Transcription results in the formation of a chimeric RNA species consisting of the t-RNA transcript fused to the foreign sequence.

-9-

Figure 2: Sequence of three DNA fragments fused to t-RNA^{i_{met}}
3-5.

5 Figure 2 shows that the DNA fragments A and B correspond to sequence found in an HIV isolate, right to left, nucleotides 530 to 559 and 5960 to 5989, respectively (33). DNA fragment C corresponds to a sequence found in M-MuLV, nucleotides 1645 to 1674 (31). Additional sequences at the
10 5' end of each DNA fragment generate a Sac II "sticky end" as indicated. At the 3' end of each fragment, additional nucleotides are present to generate a t-RNA transcription termination signal and a MluI "sticky ends", as indicated.

15 Figure 3: Structure of a retroviral vector containing a chimeric t-RNA gene.

N2 is a retroviral vector derived from M-MuLV, a murine retrovirus, which was previously described (2). The N2 vector was first modified by insertion of a 52 bp long polylinker sequence into the NheI site present in the 3'LTR. The polylinker sequence contains five restriction sites which are unique to the N2 plasmid: ApaI, Bgl II, Sna BI, Sac II, and MluI. (14). The t-RNA containing DNA fragment encoded in plasmid 3-5 (as described by Adeniyi-Jones (1)) was excised with Stu I and Bam HI, treated with Klenow fragment to generate blunt ends and cloned into the Sna BI site of the modified N2 vector. The three DNA fragments shown in Figure 2 were cloned into the Sac II and Mu I sites of the polylinker in the N2 vector. The sequences as shown
20 in Figure 2 fused to the 3' end of 3-5 will generate fusion RNA transcripts in which the foreign sequence is
25
30

-10-

complementary to HIV RNA (A and B) or M-MuLV (C). N2 vector DNA containing the chimeric t-RNA was converted to corresponding virus using established procedures as
5 described in text (14, 27). Figure 3 also shows that in the infected cell the chimeric t-RNA is duplicated and is present in both LTR's (14). LTR - long terminal repeat; Neo-Neomycin resistance gene; 3-5- tRNA^{i_{met}} derivative described in Figure 1B; seq - DNA fragments described in
10 Figure 2; T-Transcription termination signal shown in Figure 2.

Figure 4: RNA blot analysis of cells infected with antisense vectors containing chimeric t-RNAs.

15 Virus containing chimeric t-RNAs was generated by transfection of packaging cells, PA317, according to established procedures (12, 27). Total cellular RNA was isolated, subjected to electrophoresis in 8% urea-
20 polyacrylamide gels, blotted to nitrocellulose filters and hybridized with a human t-RNA^{i_{met}} probe. This probe detects both human and mouse t-RNA^{i_{met}} RNA species (13) as well as the chimeric t-RNA transcripts. Panels A, B and C show that two RNA transcripts are detected in uninfected cells (NIH
25 3T3 panel A and B; HUT 78, panel C). The larger species represents the primary RNA transcript in mouse cells and the shorter species is the mature t-RNA. (Note that the primary transcript in mouse cells is longer than that of the human cells but the size of the mature t-RNA is identical). Cells
30 harboring a chimeric t-RNA contain an additional RNA species which is detected with the t-RNA^{i_{met}} probe. This RNA species corresponds in size to the predicted size of the transcripts

-11-

expressed from the corresponding templates (see Figures 2 and 3), and it is of the same size in both human and mouse cells.

5

Panel A shows virus corresponding to DNA construct DCT5A and DCT5B which were used to infect NIH 3T3 cells. G418 resistant colonies were isolated and then pooled for RNA analysis. The variation in intensity of the chimeric t-RNA band is due to the variation in the fraction of cells harboring the correct vector DNA.

10 Panel B shows NIH 3T3 cells infected with virus corresponding to DCT5C. G418 resistant colonies were isolated (C1-C4) and analyzed independently.

15 Panel C shows HUT 78 cells infected with DCT5A virus G418 resistant colonies which were isolated in soft agar (A1-A3) and analyzed independently.

20

Figure 5: Inhibition of M-MuLV replication in NIH 3T3 cells harboring antisense vectors.

25 Cloned cell lines (10^6 cells per 6 cm plate) harboring the M-MuLV specific antisense vector DCT5C 1, 2 and 4 - (see RNA analysis, Figure 4B) and the parent vector DCT5 without the antisense sequences but containing the 3-5 t-RNA^{met} derivative (DCT5 1, 2) were infected with M-MuLV at a M.O.I. of about 2 and secretion of virus was determined 3 days post
30 infection by measuring R.T. activity in the medium (10).

-12-

Figure 6: Inhibition of viral spread in a culture of NIH 3T3 cells harboring an antisense vector.

5 NIH 3T3 cells and a clonally derived cell line harboring an antisense vector (DCT5C-2, see Figures 4 and 5) were infected with M-MuLV at a M.O.I. of 0.002 (10^6 cells per 6 cm plate). Cells were grown to semiconfluence and split 1:20. At times indicated (days 4, 6, 8 and 11) cells were
10 removed from the plate by light trypsinization and the fraction of cells harboring virus was measured by determining the presence of viral specific envelope on the cell surface using immunofluorescence staining and FACS analysis. Briefly, the trypsinized cells were reacted with
15 a M-MuLV envelope specific monoclonal antibody followed by FITC labelled goat antimouse antibody and sorted on a FACS machine. 10^4 fluorescence units were arbitrarily chosen to distinguish (gate) between negative and positive cells. The upper two panels show that in a culture of NIH 3T3 cells chronically infected with M-MuLV 91.8% cells score as
20 positively infected cells and in a culture of uninfected NIH 3T3 cells only 1.8 score as positive, i.e. constituting the experimental background of this procedure. The lower left panels show that in cultures infected with a low
25 multiplicity of virus (M.O.I. 0.002, i.e. one cell in 5000), virus infection spreads through the culture and after 8 and 11 days, 80% and 90% of cells are infected respectively. In contrast, the panels on the right show that spread of virus in cultures containing antisense vector is significantly
30 inhibited, reaching about 3% and 11% after 8 and 11 days respectively.

-13-

Figure 7: Inhibition of HIV replication in HUT 78 cells harboring antisense vectors.

5 HUT 78 cells were infected with DCT5A and DCT5B virus and a control virus (DCA - in which the human ADA minigene was inserted into the 3' LTR of the N2 vector) (14). Two days post-infection, the cells were plated in soft agar in the presence of 0.7 mg/ml G418. Resistant colonies appeared 10-
10 14 days later in cultures infected with the various vectors. Independent colonies were isolated and expanded to cell lines for further use. Expression of the chimeric t-RNA transcripts was determined in the DCT5A containing cell lines (A1-A3) as shown in Figure 4C, but was not determined
15 for the three DCA containing cell lines (control) or for the DCT5B derived cell lines (B1-B4).

20 Each cell line was infected with HIV (the virus strain used was ARV-2 (31), 10^5 cells per ml of 1:10 dilution of virus) and cells were split 1:5 every three to four days. Presence of HIV in the cell cultures was determined 14 days post HIV infection by measuring the R.T. activity in the various cell lines (average of the three control cell lines is taken as zero inhibition) is indicated for each cell line harboring
25 an antisense vector (A1-A3 and B1-B4). In four cell lines R.T. activity was undetectable (100% inhibition), in two cell lines, A2 and A3, a low level of R.T activity was detected (92% and 82% inhibition, respectively) and in one cell line B3, HIV replication was not inhibited. Since RNA analysis was not performed from DCT5B containing cell lines,
30 the most plausible explanation is that this cell line did not contain or did not express (sufficient levels) of the

-14-

antisense RNA.

Figure 8 shows the 60 base pair oligonucleotide encoding the
5 TAR sequence of the Human Immunodeficiency Virus (HIV).

Figure 9 shows inhibition of R.T. activity in TAR "decoy"
containing cells. In this experiment, the ability of HIV to
replicate in cells expressing TAR was compared to cells
10 which were treated in parallel to contain a similar vector
not expressing TAR.

Figure 10 shows inhibition of R.T. activity in TAR "decoy"
containing cells up to 24 days post infection.

15

20

25

30

35

-15-

Detailed Description of the Invention

This invention provides a stably transformed eucaryotic
5 cell, i.e., a cell into which a foreign DNA or RNA fragment
was introduced so that the foreign DNA or RNA, or its
transcript, or reverse transcript is maintained in the
progeny over many generations, comprising a pol III promoter
10 and a foreign transcribable DNA, the foreign transcribable
DNA being under the control of the pol III promoter.

The foreign transcribable DNA may be virtually any DNA
capable of being transcribed into RNA, regardless of whether
such RNA is subsequently translated into a polypeptide for
15 example, the transcribable DNA may encode an RNA capable of
acting as a false primer, i.e. a primer for the initiation
of reverse transcription; and ribozyme, i.e. an enzyme made
of RNA, not protein; an antisense RNA; or an mRNA, including
a polypeptide translatable therefrom; or a viral regulatory
20 sequence such as the HIV regulatory sequence designated TAR.
The pol III promoter may be any promoter recognized by a pol
III RNA polymerase. Examples of pol III promoters useful in
the practice of this invention include, but are not limited
to, t-RNA pol III promoter, such as human, plant or animal
25 pol III promoters or mutants or derivations including
chimeric derivatives thereof, e.g. a human t-RNA^{i_{met}} or the
3-5 derivative thereof. The foreign transcribable DNA under
the control of the pol III promoter may be introduced into
the cell by any gene transfer method. Such methods may
30 include, but are not limited to, the use of gene transfer
vectors, CAPO⁴ mediated DNA transfection or electroporation.

-16-

In one embodiment, the foreign transcribable DNA encodes antisense RNA which is complementary to a segment of an RNA encoded by a pathogen, such as a retrovirus, e.g. the Human 5 Immunodeficiency Virus (HIV) or a bacteria or a parasite. Alternatively, the transcribable DNA may encode an HIV regulatory sequence, such as the regulatory sequence designated TAR to which the HIV regulatory protein designated tat binds, to activate HIV transcription, or the 10 REV recognition signal of HIV.

The foreign transcribable DNA may encode a molecule which inhibits the expression of a gene within the cell such as an endogenous gene or a foreign gene, e.g. a viral or 15 retroviral gene present within the cell. For example, the foreign transcribable DNA may encode a recognition sequence of a regulator of gene expression which acts through binding to a DNA molecule, an RNA molecule, or a regulatory protein, within the cell.

20 The eucaryotic cell useful in the practice of this invention may be a plant or animal cell, such as a mammalian cell, e.g. a human cell, or chicken cell. The mammalian and human cells may comprise but are not limited to haematopoietic 25 stem cells.

The invention also provides a stably transformed eucaryotic cell comprising a pol III promoter and a foreign transcribable DNA, the transcribable DNA being under the 30 control of the pol III promoter, wherein the pol III promoter and the foreign transcribable DNA are present in a gene transfer vector. The gene transfer vector may be a

-17-

retroviral vector. The gene transfer retroviral vector also may comprise a chimeric t-RNA introduced into the 3' long terminal repeat (LTR) region of the retroviral vector.

5

The retroviral vectors useful in the practice of this invention are, but not limited to, the murine retrovirus designated M-MuLV; the retrovirus designated N2; and the double copy vectors designated DCT5A, DCT5B and DCT5C.

10

Additionally, in accordance with the practice of this invention, the foreign DNA molecule may be under the control of a t-RNA termination signal, and the termination signal having removed therein the 3' end processing DNA sequences.

15

The stably transformed eucaryotic cell may comprise two or more pol III promoters and two or more foreign transcribable DNAs, each under the control of one of the pol III promoters. The two or more pol III promoters may be contained within a single gene transfer vector, e.g., a retroviral vector.

20

This invention further provides a retroviral vector which comprises a chimeric t-RNA introduced into the 3' long terminal repeat (LTR) of the retroviral vector. The chimeric t-RNA may comprise a pol III promoter and a foreign transcribable DNA, the transcribable DNA being under the control of the pol III promoter. The retroviral vector also may comprise two or more pol III promoters and two or more transcribable DNAs, each under the control of one of the pol III promoters.

25

30

The foreign transcribable DNA may be virtually any DNA

-18-

capable of being transcribed into RNA, regardless of whether such RNA is subsequently translated into a polypeptide, for example, the transcribable DNA may encode an RNA capable of 5 acting as a false primer, i.e. a primer for initiation of reverse transcription; a ribozyme, i.e. an enzyme made of RNA, not protein; an antisense RNA; or an mRNA, including a polypeptide translatable therefrom; or a viral regulatory sequence such as the HIV regulatory sequence designated TAR. 10 The pol III promoter may be any promoter recognized by a pol III RNA polymerase. Examples of pol III promoters useful in the practice of this invention include, but are not limited to, t-RNA pol III promoter, such as human, plant or animal pol III promoter or mutant or derivative including chimeric 15 derivatives thereof, e.g. a human t-RNA^{i_{met}} or the 3-5 derivative thereof.

In one embodiment the foreign transcribable DNA encodes 20 antisense RNA which is complementary to a segment of an RNA encoded by a pathogen, such as a retrovirus, e.g. the Human Immunodeficiency Virus (HIV) or a bacteria or a parasite. Alternatively, the transcribable DNA may encode an HIV regulatory sequence, e.g., the TAR sequence, or the REV recognition signal of HIV.

25 The foreign transcribable DNA may encode a molecule which inhibits the expression of a gene within the cell such as an endogenous gene or a foreign gene, e.g. a viral or retroviral gene present within the cell. For example, the 30 foreign transcribable DNA may encode a recognition sequence of a regulator of gene expression which acts through binding to a DNA, an RNA molecule, or a regulatory protein, within

-19-

the cell.

5 The gene transfer retroviral vector also may comprise a chimeric t-RNA introduced into the 3' long terminal repeat (LTR) region of the retroviral vector. The retroviral vectors useful in the practice of this invention are, but are not limited to, the murine retrovirus designated M-MuLV; 10 the retrovirus designated N2; and the double copy vectors designated DCT5A, DCT5B and DCT5C. Additionally, in accordance with the practice of this invention, the foreign DNA molecule may be under the control of a t-RNA termination signal, and the termination signal having removed therein the 3' end processing DNA sequences.

15

This invention further provides stably transformed animal cells; plant cells; mammalian cells, for example, mammalian and human hematopoietic stem cells; and chicken cells, each of which contain the pol III promoter and a foreign 20 transcribable DNA, wherein the transcribable DNA is under the control of the pol III promoter, as described above. These stably transformed cells may be contained within transgenic animals, transgenic plants, transgenic mammals and transgenic chickens, respectively.

25

The transgenic animal, plant, mammal or chicken described above may contain a foreign transcribable DNA which encodes for an RNA molecule which is complementary to a segment of an RNA encoded by a pathogen. The pathogen may be, but is 30 not limited to, a retrovirus such as HIV, or a bacteria or a parasite.

-20-

A vaccine useful for immunizing a patient against HIV infection is provided by this invention which comprises an effective amount of the retroviral vector described
5 hereinabove wherein the foreign transcribable DNA encodes an HIV regulatory sequence, for example, the HIV regulatory sequence designated TAR and a suitable carrier. Suitable carriers useful in the practice of this invention include,
10 but are not limited to any pharmaceutically acceptable carrier such as sterile saline, phosphate buffered saline or an emulsion.

This invention also provides a method of producing a foreign RNA which comprises culturing the stably transformed cells described above, under conditions permitting transcription of the transcribable DNA, thereby producing the foreign RNA. This method further provides recovering the foreign RNA molecule so produced. The foreign RNA molecule may comprise, but is not limited to antisense RNA, mRNA or
20 unprocessed RNA.

This invention further provides a method of producing a polypeptide comprising culturing the stably transformed eucaryotic cells described above under conditions permitting transcription of the transcribable DNA into RNA and translation of the RNA into a polypeptide. In one embodiment of this invention, the polypeptide so produced is recovered.
25

30 This invention also provides a method of treating an Acquired Immunodeficiency Syndrome (AIDS) patient or preventing HIV infection in a patient which comprises

-21-

administering to the patient a retroviral vector as described hereinabove wherein the foreign transcribable DNA encodes for an antisense RNA molecule complementary to a segment encoded by HIV or a retroviral vector wherein the foreign transcribable DNA encodes an HIV regulatory sequence such as the sequence designated TAR. Suitable methods of administering the retroviral vector in pharmaceutical form are well known to those of ordinary skill in the art, and include but are not limited to administration of the retroviral vector in a pharmaceutically acceptable carrier. Suitable pharmaceutical carriers are described hereinabove. Suitable methods of administration include, but are not limited to administration orally, intravenously or parenterally. Administration of the vector must be in dose and in such a form such that the vector is transduced into the cell, so that the foreign DNA sequence is transcribed in an amount effective to inhibit HIV infection and/or replication.

A method of intracellularly immunizing a patient against HIV infection is also provided which comprises removing haematopoietic stem cells from the patient and infecting the removed stem cells with an effective amount of a retroviral vector described hereinabove wherein the foreign transcribable DNA encodes for an HIV regulatory sequence, such as the regulatory sequence designated TAR. The infected cells are then administered back into the patient, i.e. into the patient's bone marrow, thereby intracellularly immunizing the patient against HIV infection. For the purposes of this invention, intracellular immunization means prophylaxis as well as treatment of an infection.

-22-

Materials and Methods

The t-RNA transcriptional unit

5

Figure 1A shows the structure of a prototype mammalian t-RNA gene (ranging in size between 95-105 bp). In contrast to protein encoding genes (transcribed by pol III) the t-RNA promoter is encoded within the t-RNA gene itself, in two regions shown in Figure 1 as Box A and B. Termination of transcription is specified by a sequence present at the 3' end of the t-RNA gene (see Figure 1) which includes a run of 4 or more T nucleotides bracketed by 2 or more G or C nucleotides (on the sense strand of the DNA). Transcription of the t-RNA gene terminates in the second or third T. The RNA transcribed of the t-RNA gene, the primary transcript, is further processed resulting in the removal of sequences from the 5' and 3' end of the primary transcript, as shown in Figure 1 (9).

20

Human t-RNA^{iMet} and the 3-5 derivative

25

The human genome contains 10-12 t-RNA^{iMet} genes which are highly conserved among eucaryotes (32) (the human and mouse t-RNA^{iMet} genes are identical and do not cross-hybridize to other cellular t-RNAs (13)) and are responsible for 10-15% of total t-RNA synthesized in mammalian cells. As calculated above, expression of RNA from one t-RNA^{iMet} gene can be equal to or exceed the amount of total mRNA (pol II based) transcripts expressed in the cell. Figure 1B shows the structure of a t-RNA^{iMet} derivative, called 3-5 which was used in the studies described below. 3-5 contains a

30

35

-23-

deletion of 19 nucleotides from the 3' end of the t-RNA gene which has effectively eliminated the 3' processing signal, i.e. the removal of the sequences 3' to the mature t-RNA (1). The studies of Adeniyi-Jones (1) strongly suggests that insertion of foreign sequences between the end of the 3-5 t-RNA derivative and a termination signal will result in the synthesis of a chimeric RNA in which the bulk of the t-RNA transcript will remain fused to the foreign RNA sequence. This is illustrated in Figure 1C.

Other t-RNA derivatives, as well as other pol III, promoters (such as ribosomal 5S or adenovirus VAI promoters) can be used to affect the processing and/or cellular localization of the foreign RNA transcript. For example, by using the t-RNA^{i_{met}} derivative described by Adeniyi-Jones (1) which is called 3-2, the foreign RNA transcript will be removed and separated from the t-RNA moiety. By using t-RNA^{i_{met}} mutants as described by Tobian, et al. (35) it may be possible to direct the RNA transcripts into the nucleus or cytoplasm of the cell.

Construction of chimeric t-RNA genes

A chimeric t-RNA is a transcriptional unit formed by fusion of a foreign DNA sequence to the 3' end of a t-RNA gene or a portion of a t-RNA gene, which encodes the t-RNA promoter but lacks a transcriptional termination sequence, and a third DNA fragment fused to the 3' end of the foreign sequence which encodes a t-RNA transcription termination signal.

-24-

Using standard recombinant DNA techniques, three chimeric 3-
5 t-RNA genes were generated by fusing 29 and 30 bp long DNA
fragments to the 3' end of 3-5, followed by a short sequence
5 to specify termination of transcription (Figure 1C). The
sequences of the three DNA fragments are shown in Figure 2.
The question addressed in these studies is whether stable
gene transfer of the chimeric t-RNA genes into cultured
cells will result in the synthesis of the corresponding RNA.

10

Cloning into DC retroviral vector

A retroviral vector was used to introduce the chimeric t-RNA
genes into cultured mouse fibroblast cells. Figure 3 shows
15 the structure of the retroviral vector used, the method of
cloning and the essential features of this particular
vector. The retroviral vector is a double copy (DC) vector
called N2A and is derived from M-MuLV, a murine retrovirus
(12). The chimeric t-RNA genes were cloned into the 3' LTR
20 to generate vector constructs DCT5A, DCT5B and DCT5C. Using
established procedures, the vector DNA was converted to
corresponding virus and this virus was used to infect NIH
3T3 cells, an established mouse fibroblast cell line. In
the infected cell it is expected that the chimeric t-RNA
25 inserts will be duplicated and will appear in both 5' and 3'
LTR as shown in Figure 3, a feature that may facilitate the
expression of the hybrid t-RNA genes (14).

30

Analysis of cells infected with the chimeric t-RNA vectors
The three t-RNA based vectors described above and shown in
Figure 2 and 3 were converted to corresponding virus using

35

-25-

established procedures (14, 27). Briefly, DCT5A and DCT5B vector DNAs were transfected into PA317, an amphotropic packaging cell line (27), G418 resistant colonies were
5 pooled and supernatant was used as a source of virus to infect NIH 3T3 cells. Vector infected NIH 3T3 cells were selected in G418 and pooled colonies were analyzed. DCT5C virus was prepared by transient transfection of PA317 cells; infection of NIH 3T3 cells with supernatant collected 48
10 hours post transfection; G418 selection; and isolation of individual G418 resistant colonies were analyzed as described below. The structure of the vector DNA integrated in the NIH 3T3 cell chromosome was determined using known DNA blotting procedures and was shown to be intact (not
15 shown). [As shown in Figure 3 and discussed in an article by Hantzopoulos, et al. (14), using DC vector, the chimeric t-RNA is duplicated in the infected cell.]

RNA blot analysis was performed to determine whether the
20 cells harboring the chimeric t-RNA express the corresponding RNA in NIH 3T3 cells. Total cellular RNA was subjected to electrophoresis in 8% acrylamide-urea gels, blotted to nylon filters and hybridized with a ³²P-labelled t-RNA^{i_{met}} specific probe. The results of this analysis are shown in Figure 4A
25 and 4B. The t-RNA probe detects two RNA species in uninfected NIH 3T3 cells in the size range of 70-90 nucleotides which represent the mature t-RNA^{i_{met}} and its unprocessed form. In cells infected with the t-RNA fusion genes an additional species is detected which corresponds in
30 size to the chimeric RNA transcripts in which the t-RNA is fused to the foreign sequence.

-26-

Judging from the intensity of hybridization, the chimeric transcripts represent between 5% - 25% of total t-RNA^{i_{met}} synthesized in the cell, suggesting that they are expressed
5 very efficiently. [It is possible to estimate that if t-RNA^{i_{met}} represent 10-15% of total t-RNA, and there are 10-12 t-RNA genes per genome and t-RNAs are 100 fold more abundant than the mRNA i.e., pol II transcripts, then the chimeric t-RNA present in the cell equals (within an order of
10 magnitude) the total number of polyA+ transcripts. This would mean that the chimeric t-RNA carrying a foreign sequence is 100 fold to 10,000 fold more abundant than individual pol II transcripts. Expression of the chimeric t-RNA genes is not limited to the mouse fibroblast cell line
15 NIH 3T3. Virus supernatant corresponding to DCT5A and DCT5B was used to infect HUT 78 cells, a human T-lymphoid cells line and individual clones isolated by G418 selection were analyzed for RNA expression. As shown in Figure 4C, the chimeric t-RNA genes are equally active in this human cell
20 line.

Construction of a vector containing the HIV - TAR sequence

Construction of the N2A vector was described previously.
25 The 3-5 tRNA^{i_{met}} gene was then cloned into the Sna B1 site of the N2A vector such that transcription occurs parallel to LTR initiated transcription.

The pol III termination sequence "Ter" was cloned between
30 the Sac II-MluI sites of the N2A polylinker. This oligonucleotide sequence contains a Bam HI restriction site. Previously, other Bam HI sites were removed from the vector

-27-

using techniques known to those of ordinary skill in the art.

5 The 63 base pair TAR oligonucleotide (see Figure 8) was then cloned between the Sac II - Bam HI sites from the "Ter" oligonucleotide upstream of the pol III termination sequence. This TAR sequence is derived from the ARV-Z strain of HIV-I (31).

10 Inhibition of M-MuLV replication in cells harboring chimeric t-RNA antisense templates

15 DCT5C contains a chimeric t-RNA gene fused to a 29 nucleotide long sequence which is complementary to a portion of M-MuLV. M-MuLV is a prototype murine retrovirus which replicates efficiently in NIH 3T3 cells expressing high levels of viral RNA in the cells reaching 1-5% of total polyA+ RNA (7, 36). The ability of DCT5C to inhibit M-MuLV 20 replication represents a stringent test as to the potential of this new approach to inhibit the expression of genes and protect cells from the replication of viruses.

25 In the experiment shown in Figure 5, three NIH 3T3 derived clones harboring the DCT5C vector and two clones containing the parent vector, DCT5 (which does not contain the antisense sequence) were infected with M-MuLV at a multiplicity of infection (M.O.I.) of about 2. The ability of the cells to support the replication of M-MuLV was 30 determined by measuring the secretion of virus from the cells (determined by the appearance of reverse transcriptase (R.T.) activity in the supernatant of infected cells). As

-28-

shown in Figure 5, in cells harboring the antisense templates M-MuLV replication was inhibited 70%-95%.

5 In a second experiment to test the ability of the antisense vectors to inhibit the spread of M-MuLV in culture, the above described cell lines were infected at a M.O.I. of 0.002 and the spread of M-MuLV was monitored by FACS analysis, to determine the fraction of cells infected with
10 M-MuLV. As shown in Figure 6, presence of M-MuLV specific antisense templates in cells leads to significant inhibition in the ability of M-MuLV to spread in the culture.

15 The experiments described in this section shows that: (a) chimeric t-RNA based transcriptional units can be stably introduced into eucaryotic cells resulting in high levels of corresponding RNA expression; and (b) a M-MuLV specific antisense template fused to the t-RNA promoter results in the efficient inhibition of M-MuLV replication in the corresponding cells. Since M-MuLV is a very efficient transcriptional unit, the experiments shown in Figures 5 and 20 6 testify to the potency of a pol III based transcriptional unit.

25 Inhibition of HIV replication in cells harboring chimeric t-RNA antisense templates

DCT5A and DCT5B contain a chimeric t-RNA gene fused to 30 base-pair long nucleotide sequences, which upon 30 transcription yield RNA species which are complementary to portions of the HIV genome (see Figures 2 and 3). The ability of the two vectors, DCT5A and DCT5B, to inhibit the

-29-

replication of HIV in susceptible human lymphoid cells was tested and the results are shown in Figure 7.

5 Virus corresponding to DCT5A and DCT5B was used to infect HUT 78 cells (a human cutaneous T cell lymphoma derived cell line) and individually infected cells were cloned in soft agar in the presence of G418. Independently derived clones were tested for their ability to support the replication of
10 HIV. As a control, HUT 78 cells were infected with a virus derived from a similar vector in which an unrelated sequence (the human adenosine deaminase minigene) was introduced into the 3'LTR of the N2 derived vector. The ability of HIV to replicate in HUT 78 cells containing the antisense vectors
15 and the control vector was determined by measuring the appearance of R.T. activity in the medium. Figure 7 shows the result of such an experiment. As shown in Figure 7, replication of HIV cell lines harboring the DCT5A vector (A1-A3) is inhibited between the three cell lines and this correlates to the amount of antisense RNA present in the cell as can be seen in Figure 4C. Replication of HIV in the three cell lines harboring the vector DCT5B is virtually shut down (Figures 7, B1, B2 and B4). In one cell line, B3, HIV replication was not affected. The reason for that is
20 not known. The ability of HIV to replicate in the HUT 78 derived cell lines was also measured using in site immunofluorescence (IFA) and the results of this experiment were consistent with R.T. analysis (not shown). For example, after 14 days in culture, 40-80% of the cells in
25 the three control cell lines scored positive while no positive cells were detected in cell lines A1, B1, B2 and B4 (in a field containing about 1000 cells) and only few
30 .

-30-

positive cells were present in A2 and A3 cells, while B3 cells were indistinguishable from the control.

5 In summary, the experiments described in this section show that the stable transfer into cells of DNA constructs which consist of chimeric t-RNAs fused to HIV specific antisense templates, inhibit HIV replication. In other words, the antisense vector containing cells are protected from HIV
10 replication, and consequently from its deleterious effects.
The prospects of applying this methodology to human AIDS patients in which the antisense vectors are introduced into the patient to protect the patient from HIV replication and further progression of AIDS, represents an exciting and
15 novel strategy to combat this dreadful disease (3).

Inhibition of HIV R.T. production in "TAR" decoy cells

20 The expression of the HIV genes is regulated by the viral gene product designated tat. Binding of the tat gene product to a specific sequence on the viral RNA, called TAR, is required for HIV gene expression and generation of virus. The tat recognition sequence was mapped to the 5' end of the viral RNA to encompass 60 nucleotides or less of RNA (31).
25

A 60 base pair oligonucleotide encompassing the TAR sequence was chemically synthesized. (see Figure 8). A retroviral vector as shown in Figure 1-3 was constructed in which the TAR containing oligonucleotide is fused to a t-RNA gene and
30 inserted into the 3' LTR of the M-MuLV based N2 vector. A detailed description of the construction of this vector is described hereinabove.

-31-

In the experiment shown in Figure 9, clonal isolates of CEMSS cells, an HIV-1 susceptible human T-cell line harboring TAR - containing vectors or a control vector were
5 infected with HIV-1 at a multiplicity of infection (M.O.I.) of about 2. The ability of the vector to efficiently synthesize TAR and thereby inhibit the replication of HIV was determined by measuring the secretion of virus from the cells (determined by the appearance of reverse transcriptase
10 (R.T.) activity in the supernatant of infected cells). As shown in Figure 9, two clonal isolates of CEMSS cells that were characterized to harbor the control vector did support HIV replication. This is documented by the appearance of reverse transcriptase (R.T.) activity in the media.

15 On the other hand, in two cloned CEMSS isolates characterized to harbor and express the TAR sequences, HIV replication was significantly inhibited, i.e., in a range from 90-95% inhibition.
20

Figure 10 shows the results of a separate experiment which was conducted as described above, except that R.T. activity was measured at intervals up to 24 days post infection. As can be seen in Figure 10, not only is HIV replication
25 significantly inhibited as compared to the control at 14 days post infection, but the duration of the inhibitory effect was established up to 24 days post infection.

30 The experiments shown in Figures 9 and 10 clearly demonstrate that the synthesis of a chimeric TAR containing transcript acts as "decoy" to bind the tat gene product synthesized in the HIV infected cells, thereby preventing

-32-

the binding of tat to its physiological target, the TAR sequence in the HIV genome. This leads to the lack of activation of HIV gene expression and inhibition of HIV replication in cultured CEMSS cells.

Potential applications of pol III based transcriptional units mediated via stable gene transfer

10 The ability to synthesize high levels of specific RNA transcripts in eucaryotic cells in a genetically stable manner offers wide range of useful applications and a few examples are listed below.

15 Protection of human patients from infectious pathogens

Antisense RNA inhibition protocols mediated via stable gene transfer can be used to render cells resistant to the replication of pathogens. The strategy involves the 20 introduction, via an antisense vector, of antisense templates, i.e., a DNA molecule encoding a transcriptional unit, which upon introduction into a cell is capable of synthesizing an antisense RNA molecule, into the uninfected cell to express constitutively antisense RNA specific to a 25 given pathogen. When challenged with the pathogen, expression of its genes or any other aspect of its replication will be inhibited and consequently pathogen replication in the cell and spread to other cells will be limited. The feasibility of such a strategy to inhibit the 30 replication of HTLV-I, a human retrovirus, in human T-lymphoid cells was recently demonstrated (30) and the experiments shown in Figures 5 and 6 demonstrated that t-RNA

-33-

based antisense templates are effective in protecting cells from M-MuLV replication. The application of this technology to the treatment of AIDS and other pathogen caused diseases 5 can be considered (3). It may be also possible to use antisense RNA technology to inhibit other genes which are deleterious to human patients such as oncogenes.

10 Generation of animals and plant breeds (transgenic) which are resistant to pathogens

15 Generation of transgenic animals and plants which carry effective antisense templates can be used to generate new animal and plant breeds which are resistant to a host of pathogens. Antisense RNA based strategies have been used with limited success to generate transgenic plants, in many cases achieving a level of inhibition insufficient to provide effective protection from pathogens (22).

20 The experiments described in the previous section have shown that pol III based promoters can be used to express in a genetically stable manner, high levels of desired RNA transcripts in the eucaryotic cell, and may be useful in the generation of animal and plant breeds carrying effective 25 antisense templates. The same technology can be also used in a general way to inactivate specific genes in transgenic animal or plants. This can be used as a means to regulate various functions and properties of the transgenic breeds (21) or to introduce specific mutations to generate model 30 systems for human genetic disorders (19), or to investigate consequences of gene dysfunction.

-34-

Additional strategies of gene inhibition which require efficient RNA synthesis

5 The concept of gene inhibition via stable gene transfer was recently discussed in a commentary in Nature and termed "intracellular immunization" because it can be used to protect a cell from the replication of infectious pathogens (3). There are potentially a large number of mechanisms
10 that can be employed for this purpose (i.e., gene inhibition) antisense RNA inhibition being one such approach. Another strategy, involving the design of a defective regulatory protein which functions as a competitive inhibitor during gene expression and replication
15 of Herpes Simplex Virus (HSV), also was described (8).

20 One particular application which involves the use of a regulatory protein which functions as a competitive inhibitor to bind to an HIV protein necessary for activating transcription of HIV genes, involves the vector construct containing TAR sequences.

25 In this "intracellular immunization" therapy, bone marrow cells would be taken from a patient, including all the important haematopoietic stem cells. The stem cells will then be infected with the TAR-containing retroviral vector, in an amount which is effective to produce an amount of the TAR oligonucleotide decoy, such that the HIV tat protein
30 binds to the TAR decoys and is competed away from binding to the HIV genome, thereby inhibiting the activation of transcription.

-35-

- These modified stem cells will then be injected into the patient and back to the bone marrow by methods well known to those of ordinary skill in the art. Radiation therapy or
5 the administration of a cytotoxic drug to the patient may be used to facilitate the growth of the implanted cells. This "intracellular immunization" therapy would be useful not only to treat HIV positive patients, but would also be useful to prevent HIV infection.
10 This section describes three strategies for genes inhibition which differ from the antisense inhibition strategy which involves the formation of stable RNA:RNA or RNA:DNA hybrids as described by Weintraub, et al. (37), Coleman et al. (5),
15 and van der Krol, et al. (22). The common denominator of the three strategies is their dependence on the ability to express high levels of specific RNAs in the cell, which is the subject of this invention.

20 False priming

This approach is useful for the inhibition of replication of retroviruses such as HIV, the etiological agent of AIDS. Upon penetration of a virus into the cell, one of the earliest events in its replication involves the reverse transcription of the viral RNA genome into a double stranded DNA form. This reaction is carried out by a virus specific enzyme called reverse transcriptase (R.T.). Initiation of reverse transcription occurs via a priming reaction in which 25 a cellular t-RNA bound to a specific region of the viral genome serves as a primer. Elongation involves not only synthesis of the DNA strand but it also involves the
30

-36-

degradation of the RNA template by an RNase H activity which is part of or physically associated with reverse transcriptase (36).

5

The strategy of false priming involves the synthesis of specific primers which will initiate reverse transcription and virion RNA degradation at various locations throughout the viral genome, and hence lead to abrogation of the 10 replication cycle.

15 The advantage of false priming as compared to antisense RNA inhibition which requires the formation of thermodynamically stable RNA:RNA hybrids is that it: (a) does not require the formation of stable hybrids; and (b) results in the irreversible inhibition (via degradation) of the target RNA.

Gene inhibition via false priming requires the synthesis of 20 RNA which is complementary to the target RNA throughout its 3' end (to which the DNA strand is added). Consequently, pol II based transcriptional units cannot be used to inhibit genes via false priming because pol II transcripts contain 25 a stretch of poly A at their 3' end. On the other hand, pol III based transcriptional units are uniquely suited to inhibit genes via false priming because they can be used to generate the required RNA primers. The unique mechanism of 30 RNA termination of pol III transcripts enables the design of specific transcripts which are complementary throughout the 3' end to a given RNA template and therefore can act as primers for reverse transcription. Briefly, pol III terminates transcription in a run of Ts, four or more, which is bracketed by a region of G and/or C nucleotides (9). The

-37-

pol III transcript terminates after the second or third T. Consequently, a primer can be generated to correspond to a specific region of the retroviral genome which contains at 5 the 3' end the sequence (G or C)₂AAA. The primer sequence which can be synthesized chemically, is fused to a pol III promoter at the 5' end. At the 3' end, the primer will contain an additional sequence of two or three T nucleotides, followed by several G and/or C nucleotides to 10 regenerate a pol III transcription termination signal.

Gene inactivation via ribozymes

Haseloff and Gerlach (15) have recently shown that it is 15 possible to cleave RNA molecules at specific sequences using artificial ribozymes. This experimental strategy can be used to inactivate specific genes by designing a transcriptional unit encoding such ribozymes.

20 Functional inactivation of gene regulators

Another approach which requires the efficient synthesis of specific RNA species in the cell, may be used to functionally inactivate gene activators or inhibitors and 25 consequently inhibit or activate gene expression. For example, the HIV encoded rev gene product is a gene activator and regulates the expression of the HIV genome in the infected cell via direct binding to a specific sequence on the HIV genome called RRE (12, 24). By engineering a 30 cell which expresses high levels of an RNA transcript containing the RRE sequence, the rev gene will bind to this RNA and therefor will not be available for binding to the

-38-

HIV RRE sequence. Consequently, the HIV genes will not be expressed, thereby inhibiting HIV production and spread.

5 In a similar fashion it may be possible to use t-RNA promoter based RNA transcriptional units to inactivate the function of gene regulators which mediate their function by binding to specific DNA sequences. This can be achieved by designing a DNA template that generates an RNA transcript
10 containing a palindrome which will fold into a double stranded structure containing the sequence corresponding to the recognition sequence of the DNA binding gene regulator. The presence of high levels of double stranded RNA forms of the recognition sequence, compared to only two copies of the
15 actual DNA sequence in the cell, may compete effectively for the DNA binding protein.

Large scale production of proteins in eucaryotic cells

20 The advent of genetic engineering opened the door to the large scale production of specific proteins which in turn spawned a whole new biotechnology industry. Although bacteria are the host of choice in this process, in many cases it is necessary to use mammalian cell based production
25 systems to obtain biologically active products. Mammalian cell based production systems are more complex, expensive and far less efficient in protein synthesis in comparison to bacterial based systems. Presently, the main strategy used to improve the production of genetically engineered proteins
30 in mammalian cells involves the co-amplification of the corresponding gene which is fused to an amplifiable gene such as DHFR. The major limitation of this approach is that

-39-

the amplification process requires about 8-12 months and is fraught with uncertainties, mainly due to the frequent loss of the desired gene during the amplification process.

5

The experiments described hereinabove offer an alternative approach for the large scale production of proteins in mammalian cells because it generates 100-10,000 fold higher levels of RNA transcripts in the cell as compared to conventionally employed pol II based transcriptional unit systems. The pol III based system can potentially produce mRNA for protein synthesis without the lengthy amplification process.

10
15

20

25

30

35

-40-

References

- 5 1. Adeniyi-Jones, S., Romeo, P.H. and Zasloff, M. (1984). Generation of long read-through transcripts in vivo and in vitro by deletion of 3' termination and processing sequences in the human tRNA^{Met} gene. Nucl. Acid Res. 12: 1101-1115.
- 10 2. Armentano, D., Yu, S-F, Kantoff, P.W., von Ruden, T., Anderson, W.F., and Gilboa, E. (1987). Effect of internal viral sequences on the utility of retroviral vectors. J. of Virol. 61: 1647-1650.
- 15 3. Baltimore, D., (1988). Intracellular immunization. Nature. 335: 395-396.
- 20 4. Chang, L-J., Stoltzfus, C.M. (1985). Gene expression from both intronless and intron-containing Rous sarcoma virus clones is specifically inhibited by antisense RNA. Mol. Cell. Biol. 5: 2341-2348.
- 25 5. Coleman, J., Hirashima, A., Inokuchi, Y., Green, P.J. and Inouye, M. (1985). A novel immune system against bacteriophage infection using complementary RNA (mic RN). Nature. 315: 601-603.
- 30 6. De la Pena, P. and Zasloff, M., (1987). Enhancement of mRNA nuclear transport by promoter elements. Cell. 50: 613-619.
- 35 7. Fan, H. and Baltimore, D. (1973). RNA metabolism of

-41-

murine leukemia virus: Detection of virus-specific RNA sequences in infected cells and identification of virus-specific messenger RNA. J. Mol. Bio. 80: 93-117.

5

8. Friedman, A.D., Triezenberg, S.J. and McKnight, S.L. (1988). Expression of a truncated viral trans-activator selectively impedes lytic infection by its cognate virus. Nature. 335: 452-454.
- 10
9. Geiduschek, E.P. (1988). Transcription by RNA polymerase III. Ann. Rev. Biochem. 57: 873-914.
- 15
10. Goff, S., Traktman, P. and Baltimore, D., (1981). Isolation and properties of Moloney murine leukemia virus mutants: Use of rapid assay for release of virion reverse transcriptase. J. of Virol. 38: 239-248.
- 20
11. Green, P.J., Pines, O. and Inouye, M. (1986). The role of antisense RNA in gene regulation. Ann. Rev. Biochem. 55: 569-597.
- 25
12. Hadzopoulou-Cladaras, M., Felber, B.K., Cladaras, C., Anthanassopoulos, A., Tse, A. and Pavlakis, G.N. (1989). The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J. of Virol. 63: 1265-1274.
- 30
13. Han, J.H., Rooney, R.J. and Harding, J.D. (1984). Structure and evolution of mammalian tRNA genes:

35

-42-

sequence of a mouse tRNA^{iMet} gene, the 5'-flanking region of which is homologous to a human gene. Gene. 28: 249-255.

5

14. Hantzopoulos, P.A., Sullenger, B.A., Unger, G. and Gilboa, E. (1989). Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit to a retroviral vector. Proc. Natl. Acad. Sci. USA. (In Press).
15. Haseloff, J. and Gerlach, W.L. (1988). Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334: 585-591.
16. Izant, J.G. and Weintraub H. (1984). Inhibition of thymidine kinase gene expression by antisense RNA: A molecular approach to genetic analyses. Cell 36: 1007-1015.
17. Izant, J.G. and H. Weintraub (1985). Constitutive and conditional suppression of exogenous and endogenous genes by antisense RNA. Science. 229: 345-352.
18. Jennings, P.A. and Molloy, P.L., (1987). Inhibition of SV40 replicon function by engineered antisense RNA transcribed by RNA polymerase III. The EMBO Journal 6: 3043-3047.
19. Katsuki, M., Sato, M., Kimura, M., Yokoyama., M. Kobayashi, K, and Nomura (1988). Conversion of normal behavior to shiverer by myelin basic protein antisense

-43-

cDNA in transgenic mice. *Science* 241: 593-595.

- 5 20. Kim, S.K., Wold, B.J. (1985). Stable reduction of thymidine kinase activity in cells expressing high levels of antisense RNA. *Cell* 42: 129-138.
- 10 21. van der Krol, A.R., Lenting, P.E., Veenstra, J., van der Meer, I.M., Koes, R.E., Gerats, A.G.M., Mol, J.N.M. and Stuitje, A.R. (1988). An antisense chalcone synthase gene in transgenic plants inhibits flower pigmentation. *Nature*. 333: 866-869.
- 15 22. van der Krol, A.R., Mol, J.N.M., and Stuitje, A.R., (1988). Modulation of eukaryotic gene expression by complementary RNA or DNA sequences. *BioTechniques*. 6: 958-976.
- 20 23. Lewis, D.E. Manley, J.L. (1986). Polyadenylation of an mRNA precursor occurs independently of transcription by RNA polymerase II in vivo. *Proc. Natl. Acad. Sci. USA* 83: 8555-8559.
- 25 24. Malim, M.H., Hauber, J., Le, S.-Y., Maizel, J.V. and Cullen, B.R. (1989). The HIV-1 rev transactivator acts through a structures target sequence to activate nuclear export of unspliced viral mRNA. *Nature* 338: 254-257.
- 30 25. McGarry, T.J. and Lindquist, S. (1986). Inhibition of heat shock protein synthesis by heat-inducible antisense RNA. *Proc. Natl. Acad. Sci. USA* 83: 399-403.

-44-

26. Melton, D. (1985). Injected antisense RNAs specifically block messenger RNA translation in vivo. Proc. Natl. Acad. Sci. USA. 82: 144-148.
- 5
27. Miller, A.D., and Buttimore, C., (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6: 2895-2902.
- 10
28. Paterson, B.M., Roberts, B.E. and Kuff, E.L. (1977). Structural gene identification and mapping by DNA mRNA hybrid-arrest cell-free translation. Proc. Natl. Acad. Sci. USA 74: 4370-4374.
- 15
29. Pestka, S., Daugherty, B.L., Jung, V., Hotta, K. and Pestka, R.K. (1984). Anti-mRNA: Specific inhibition of translation of single RNA molecules. Proc. Natl. Acad. Sci. USA 81: 7525-7528.
- 20
30. von Ruden, T. and Gilboa, E., (1989). Inhibition of human t-cell leukemia virus type I replication in primary human T cells that express antisense RNA. J. of Virol. 63: 677-682.
- 25
31. Sanchez-Prescador, R., Power, M.D., Barr, P.J., Steimer, K.S., Stempien, M.M., Brown-Shimer, S.L., Gee, W.W., Renard, A., Randolph, A., Levy, J.A., Dina, D., and Luciw, P.A. (1985). Nucleotide sequence and expression of an AIDS-Associated Retrovirus (ARV-2). Sci. 277: 484-492.
- 30

-45-

32. Santos, T. and Zasloff, M. (1981). Comparative analysis of human chromosomal segments bearing nonallelic dispersed tRNA^{i_{met}} genes. *Cell* **23**: 699-709.
- 5
33. Shinnick, T.M., Lerner, R.A., and Sutcliffe, J.G. (1981). Nucleotide sequence of Moloney murine leukemia virus. *Nature* **293**: 543-548.
- 10
34. Sisodia, S.S., Sollner-webb, B., Cleveland, D.W. (1987). Specificity of RNA maturation pathways: RNAs transcribed by RNA polymerase III are not substrates for splicing or polyadenylation. *Mol. Cell Biol.* **7**: 3602-3612.
- 15
35. Tobian, J.A., Drinkard, L., and Zasloff, M. (1985). tRNA nuclear transport: Defining the critical regions of human tRNA^{i_{met}} by point mutagenesis. *Cell* **43**: 415-422.
- 20
36. Varmus, H. and Swanstrom, L., (1982). Replication of retroviruses. (R. Weiss, N. Teish, H. Varmus and J. Coffin, eds.) *RNA Tumor Viruses*, Cold Spring Harbor Press, Cold Spring Harbor, New York. 369-512.
- 25
37. Weintraub, H., Izant, J.G., Harland, R.M., (1985). Antisense RNA as a molecular tool for genetic analysis. *Trends in Genetics*. **2**: 22-25.
- 30
38. Zamecnik, P.C. and Stephenson, M.L. (1978). Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

-46-

Proc. Natl. Acad. Sci. USA 75: 280-284.

- 5 39. Molecular and Cell Biology (1986) J. Darnell, H.
Lodish, D. Baltimore, eds., Scientific American Books,
New York, New York, p. 137, Table 5-3.

10

15

20

25

30

35

-47-

What is claimed is:

- 5 1. A stably transformed eucaryotic cell comprising a pol III promoter and a foreign transcribable DNA, the foreign transcribable DNA being under the control of the pol III promoter.
- 10 2. A stably transformed eucaryotic cell of claim 1, wherein the foreign transcribable DNA encodes a false primer.
- 15 3. A stably transformed eucaryotic cell of claim 1, wherein the foreign transcribable DNA encodes a ribozyme.
- 20 4. A stably transformed eucaryotic cell of claim 1, wherein the foreign transcribable DNA encodes an antisense RNA.
- 25 5. A stably transformed eucaryotic cell of claim 1, wherein the foreign transcribable DNA encodes an mRNA.
- 30 6. A stably transformed eucaryotic cell of claim 1, wherein the foreign transcribable DNA encodes a polypeptide.
- 35 7. A stably transformed eucaryotic cell of claim 1, wherein the pol III promoter comprises a t-RNA or a mutant or derivative thereof.
8. A stably transformed eucaryotic cell of claim 7,

-48-

wherein the pol III promoter comprises a human t-RNA or a mutant or derivative thereof.

- 5 9. A stably transformed eucaryotic cell of claim 8, wherein the pol III promoter comprises a t-RNA^{i_{met}} or a mutant or derivative thereof.
- 10 10. A stably transformed eucaryotic cell of claim 8, wherein the pol III promoter comprises a plant pol III promoter or a mutant or derivative thereof.
- 15 11. A stably transformed eucaryotic cell of claim 8, wherein the pol III promoter comprises an animal pol III promoter or a mutant or derivative thereof.
- 20 12. A stably transformed eucaryotic cell of claim 1, wherein the foreign transcribable DNA encodes a molecule which inhibits expression of a gene within the cell.
- 25 13. A stably transformed eucaryotic cell of claim 4, wherein the antisense RNA comprises RNA which is complementary of a segment to an RNA encoded by a pathogen.
- 30 14. A stably transformed eucaryotic cell of claim 13, wherein the RNA encoded by pathogen comprises mRNA.
- 35 15. A stably transformed eucaryotic cell of claim 13, wherein the pathogen comprises the Human Immunodeficiency Virus (HIV).

-49-

16. A stably transformed eucaryotic cell of claim 15,
5 wherein the foreign transcribable DNA encodes the
recognition signal of the HIV gene product designated
REV.
17. A stably transformed eucaryotic cell of claim 1,
10 wherein the foreign transcribable DNA encodes an HIV
regulatory sequence.
18. A stably transformed eucaryotic cell of claim 17,
15 wherein the HIV regulatory sequence is the HIV sequence
designated TAR.
19. A stably transformed eucaryotic cell of claim 1,
20 wherein the foreign transcribable DNA encodes a
recognition sequence of a regulator of gene expression
molecule which acts through binding to a DNA molecule or an RNA
molecule.
20. A stably transformed eucaryotic cell of claim 1,
25 wherein the eucaryotic cell comprises an animal cell.
21. A stably transformed eucaryotic cell of claim 20,
wherein the animal cell comprises a mammalian cell.
22. A stably transformed eucaryotic cell of claim 21,
30 wherein the mammalian cell comprises a human cell.
23. A stably transformed eucaryotic cell of claim 20,
wherein the animal cell comprises a chicken cell.

-50-

24. A stably transformed mammalian cell of claim 21, wherein the mammalian cell comprises a haematopoietic stem cell.
5
25. A stably transformed human cell of claim 22, wherein the human cell comprises a haematopoietic stem cell.
- 10 26. A stably transformed eucaryotic cell of claim 1, wherein the eucaryotic cell comprises a plant cell.
- 15 27. A stably transformed eucaryotic cell of claim 1, wherein the pol III promoter and the foreign transcribable DNA are present in a gene transfer vector.
20
28. A stably transformed eucaryotic cell of claim 27, wherein the gene transfer vector is a retroviral vector.
25
29. A stably transformed eucaryotic cell of claim 28, wherein the retroviral vector comprises a chimeric t-RNA introduced into the 3' long terminal repeat (LTR) region of the retroviral vector.
30
30. A stably transformed eucaryotic cell of claim 28, wherein the retroviral vector comprises the murine retrovirus designated M-MuLV.
35
31. A stably transformed eucaryotic cell of claim 28, wherein the retroviral vector comprises the retrovirus designated N2.

-51-

32. A stably transformed eucaryotic cell of claim 28, wherein the retroviral vector comprises the retrovirus designated DCT5A.
5
33. A stably transformed eucaryotic cell of claim 28, wherein the retroviral vector comprises the retrovirus designated DCT5B.
- 10 34. A stably transformed eucaryotic cell of claim 28, wherein the retroviral vector comprises the retrovirus designated DCT5C.
- 15 35. A stably transformed eucaryotic cell of claim 29, wherein the chimeric t-RNA comprises a foreign DNA molecule under the control of a t-RNA termination signal, and the termination signal having removed therefrom the 3' end processing DNA sequences.
- 20 36. A stably transformed eucaryotic cell of claim 1 comprising two or more pol III promoters and two or more foreign transcribable DNAs, and each of the foreign transcribable DNAs being under the control of one of the pol III promoters.
25
37. A retroviral vector which comprises a chimeric t-RNA introduced into the 3' long terminal repeat (LTR) of the retroviral vector.
- 30 38. A retroviral vector of claim 36, wherein the chimeric t-RNA comprises a pol III promoter and a foreign transcribable DNA, the transcribable DNA being under

-52-

the control of the pol III promoter.

- 5 39. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes a false primer.
- 10 40. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes a ribozyme.
- 15 41. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes antisense RNA molecule.
- 20 42. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes an mRNA molecule.
- 25 43. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes a polypeptide.
- 30 44. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes a viral regulatory sequence.
- 35 45. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes an HIV regulatory sequence.
- 40 46. A retroviral vector of claim 44, wherein the HIV regulatory sequence is the HIV regulatory sequence designated TAR.
- 45 47. A retroviral vector of claim 38, wherein the pol III promoter comprises a t-RNA or a mutant or derivative thereof.

-53-

48. A retroviral vector of claim 38, wherein the pol III promoter comprises a human t-RNA or a mutant or derivative thereof.
5
49. A retroviral vector of claim 38, wherein the pol III promoter comprises t-RNA^{i_{met}} or a mutant or derivative thereof.
10
50. A retroviral vector of claim 38, wherein the pol III promoter comprises a plant pol III promoter or a mutant or derivative thereof.
15
51. A retroviral vector of claim 38, wherein the pol III promoter comprises an animal pol III promoter or a mutant or derivative thereof.
20
52. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes a molecule which inhibits expression of a gene within the cell.
25
53. A retroviral vector of claim 41, wherein the antisense RNA molecule comprises an RNA molecule which is complementary of a segment of an RNA encoded by a pathogen.
30
54. A retroviral vector of claim 53, wherein the RNA encoded by the pathogen comprises mRNA.
35
55. A retroviral vector of claim 53, wherein the pathogen comprises the Human Immunodeficiency Virus (HIV).

-54-

56. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes the recognition signal of the HIV molecule designated REV.
- 5
57. A retroviral vector of claim 38, wherein the foreign transcribable DNA encodes a recognition sequence of a regulator of gene expression which acts through binding to a DNA molecule or an RNA molecule.
- 10
58. A retroviral vector of claim 38, wherein the retroviral vector comprises the murine retrovirus designated M-MuLV.
- 15
59. A retroviral vector of claim 38, wherein the retroviral vector comprises the retrovirus designated N2.
60. A retroviral vector of claim 38, wherein the retroviral vector comprises the retrovirus designated DCT5A.
- 20
61. A retroviral vector of claim 38, wherein the retroviral vector comprises the retrovirus designated DCT5B.
- 25
62. A retroviral vector of claim 38, wherein the retroviral vector comprises the retrovirus designated DCT5C.
63. A retroviral vector of claim 37, wherein the retroviral vector comprises two or more pol III promoters and two or more foreign transcribable DNAs, and each of the foreign transcribable DNAs being under the control of one of the pol III promoters.
- 30
35

-55-

64. A transgenic animal comprising a stably transformed animal cell of claim 20.
- 5 65. A transgenic mammal comprising a stably transformed mammalian cell of claim 21.
- 10 66. A transgenic chicken comprising a stably transformed chicken cell of claim 23.
- 15 67. A transgenic mammal comprising a stably transformed mammalian cell of claim 24.
- 15 68. A transgenic plant comprising a stably transformed plant cell of claim 26.
- 20 69. A transgenic animal of claim 65, wherein the foreign transcribable DNA encodes an RNA molecule which is complementary to a segment of an RNA encoded by a pathogen.
- 25 70. A transgenic mammal of claim 64, wherein the foreign transcribable DNA encodes an RNA molecule which is complementary to a segment of an RNA encoded by a pathogen.
- 30 71. A transgenic plant of claim 68, wherein the foreign transcribable DNA encodes an RNA molecule which is complementary to a segment of an RNA encoded by a pathogen.

-56-

72. A transgenic animal of claim 69, wherein the pathogen comprises HIV.
- 5 73. A transgenic animal of claim 64, wherein the foreign transcribable DNA encodes an HIV regulatory sequence.
- 10 74. A transgenic animal of claim 73, wherein the HIV regulatory sequence comprises the HIV regulatory sequence designated TAR.
75. A transgenic animal of claim 73, wherein the transgenic animal is a mammal.
- 15 76. A gene transfer vector which comprises the retroviral vector of claim 37, wherein the retroviral vector has two or more pol III promoters and two or more foreign transcribable DNAs, and each of the foreign transcribable DNAs being under the control of one of the pol III promoters.
- 20 77. A vaccine useful for immunizing a patient against HIV infection which comprises an effective immunizing amount of the retroviral vector of claim 46 and a suitable carrier.
- 25 78. A method of producing a foreign RNA which comprises culturing the stably transformed eucaryotic cell of claim 1, under conditions permitting transcription of the transcribable DNA and thereby producing the foreign RNA.

-57-

79. A method of claim 78, further comprising recovering the foreign RNA molecule so produced.
- 5 80. A method of claim 78, wherein the RNA molecule comprises antisense RNA.
- 10 81. A method of claim 78, wherein the RNA molecule comprises an mRNA molecule.
- 15 82. A method of producing a polypeptide comprising culturing the stably transformed eucaryotic cell of claim 1 under conditions permitting transcription of the transcribable DNA into RNA and translation of the RNA into the polypeptide and thereby producing a polypeptide.
- 20 83. A method of claim 82, further comprising recovering the polypeptide so produced.
84. A method of treating an Acquired Immunodeficiency Syndrome (AIDS) patient which comprises administering to the patient the retroviral vector of claim 46.
- 25 85. A method of treating an Acquired Immunodeficiency Syndrome (AIDS) patient which comprises administering to the patient the retroviral vector of claim 46.
- 30 86. A method of immunizing a patient against HIV infection which comprises administering to the patient an effective immunizing amount of the vaccine of claim 77.

-58-

87. A method of intracellularly immunizing a patient against HIV infection which comprises:

- 5 a) removing haematopoietic stem cells from the patient;
- 10 b) infecting the removed haematopoietic stem cells with effective amount of the retroviral vector of claim 46; and
- 15 c) injecting back into the patient the retroviral infected haematopoietic cells to intracellularly immunize a patient against HIV infection.

20

25

30

35

1 / 12




FIGURE 1A

2 / 12




FIGURE 1B

3 / 12




FIGURE 1C

A.**SACII****TERMINATION MLU I**

5'-GGACACTACTGAAGCACTCAAGGCAAGCTTTGCTA-3'
3'-CGCCTGTGATGAACCTCGTGAGTCGTTGAAAACGATGC-5'

B.**SACII****TERMINATION MLU I**

5'-GGCTTCCCTGCCATAGGAGATGCCCTAACGCTTTGGCA-3'
3'-CGCCGAAGGACGGTATCCTCTACGGATTGGAAAACCGTGC-5'

C.**SACII****TERMINATION MLU I**

5'-GGCCAATGGTGGGGCTTCTGCCCGCTTTGGAA-3'
3'-CGCCGGTTAACCAACCCGAAGACGGCGAAAAACCTGC-5'

5 / 12





FIGURE 3

6 / 12

FIGURE 4



7 / 12


**INHIBITION OF MLV R.T. IN 3T3 CELL
LINES CONTAINING ANTISENSE VECTORS**


FIGURE 5

WO 90/13641

PCT/US90/02656


8 / 12

WILLY
♦ ♦ ♦




CONTROL


DAY 4




DAY 8



DAY 9




DAY 11



PCT/US90/02656

8 / 12

WILLY
♦ ♦ ♦



DC15C-1







FIGURE 6

9 / 12


INHIBITION OF HIV R.T. IN HUT78 CELLS

FIGURE 7

10/12

FIGURE 8


TAR SEQUENCE OLIGONUCLEOTIDE

CODING SEQUENCE

5' **SAC II** **BGL II**
 GG/G GTC TCT CTG GTT AGA CCA GAT CTG AGC


BAM HI
CTG GGA GCT CTC TGG CTA ACT AGG GAA CCC AC/G

11/12

FIGURE 9

12/12

FIGURE 10
INHIBITION OF HIV-I R.T. PRODUCTION IN TAR DECOY CELLS



INTERNATIONAL SEARCH REPORT

International Application No. PCT/US90/02656

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ³

According to International Patent Classification (IPC) or to both National Classification and IPC

**IPC(5): C12N 15/00, 7/00, 5/00; C12P 21/00, 19/30; A61K 39/12, 37/00
U.S. CL.: 435/172.3, 235, 320, 240.2, 240.4, 255, 69.1, 89; 424/89, 93**

II. FIELDS SEARCHED

Minimum Documentation Searched ⁴

Classification System	Classification Symbols
U.S.	435/172.3, 235, 320, 240.2, 240.4, 255, 69.1, 89
	424/89, 93

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched ⁵

DIALOG Databases: BIOTECH (1969-1990), CAS (1969-1990)

III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴

Category ⁶	Citation of Document, ¹⁴ with indication, where appropriate, of the relevant passages ¹⁷	! Relevant to Claim No. ¹⁴
	SEE ATTACHED SHEETS	

* Special categories of cited documents: ¹⁵

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search ⁸

29 AUGUST 1990

Date of Mailing of this International Search Report ⁹

28 SEP 1990

International Searching Authority ¹⁰

ISA/US

Signature of Authorized Officer ¹⁰

BETH A. BURROUS
Beth A. Burrous

Attachment to Form PCT/ISA/210 (second sheet) #1

Part III. Documents considered to be relevant

Category	Citation	Claim No.
Y	Nucl. Acid. Res., Volume 11, number 6, published 1983. D. Jolly, et al. "Elements in the long terminal repeat of murine retroviruses stable transformation by thymidine kinase gene," pp. 1855-1872. see entire document.	1-67 69-70 72-87
Y	EMBO J., Volume 6, number 10, published October 1987. P. Jennings, et al. "Inhibition of SV40 replicon function by engineered antisense RNA transcribed by RNA polymerase III" pp. 3043-3047. see entire article.	1-67 69-70 72-87
Y	J. Virol., Volume 63, number 3, published March 1989. M. Hadzopoulou-Cleadas, et al. "The <u>rev</u> (<u>trs/art</u>) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a <u>cis</u> -acting sequence in the <u>env</u> region" pp. 1265-1274. see entire article.	13-19 32-34 44-46 52-57 59-62 70-74 77,84-87
Y,P	Chemical Abstracts, Volume 111, no. 13, issued 1989, September 25 (Columbus, Ohio, U.S.A.). E. Gilboa, et al. "Retroviral gene transfer: applications to human therapy" see page 110247, column 1, the abstract no. 110249f, Adv. Exp. Biol. Med. 1988, 241 (Mol. Biol. Hemopoiesis), 29-33 (Eng).	1-67 69-70 72-87
Y	Nature, Volume 335, published 29 September 1988. D. Baltimore "Intracellular Immunization" pp. 395-396. see entire article.	87

Attachment to Form PCT/ISA/210 (second sheet) #2

- Y Nature, Volume 335, published 29 September 1988. 1-87
A. Friedman, et al. "Expression of a truncated viral
trans-activator selectively impedes lytic infection
by its cognate virus" pp. 452-454. see entire article.
- Y Nucl. Acid. Res., Volume 12, number 2, published 1984. 1-87
S. Adeniyi-Jones, et al. "Generation of long read-through
transcripts in vivo and in vitro by deletion of 3' termin-
ation and processing sequences in the human tRNA (i)(met)
gene" pp. 1101-1115. see entire article.
- Y Cell, Volume 43, published December 1985. J. Tobian, 1-87
et al. "tRNA nuclear transport: defining the critical re-
gions of human tRNA (i)(met) by point mutagenesis"
pp. 415-422. see entire article.
- Y J. Virol., Volume 63, number 2, published February 1989. 1-87
T. von Ruden, et al. "Inhibition of human T-cell leukemia
virus type I replication in primary human T cells that
express antisense RNA" pp. 677-682. see entire article.
- Y Nature, Volume 323, published 25 September 1986. 77,
J. Zarling, et al. "T-cell responses to human AIDS 84-86
virus in macaques immunized with recombinant virus"
pp. 344-346. see entire article.
- Y US, A, 4,497,796 (SALSER ET AL.) 05 February 1985. 64-67
See entire document. 69,70
72-75
- Y Cold Spring Harbor Sym. on Mol. Biol., Volume LI. 64-67
published 1986. A. Miller, et al. "Transfer of genes into 69,70
human somatic cells using retrovirus vectors" pp. 1013- 72-76
1019. see entire article.

PCT US90/02656

Attachment to Form PCT/ISA/210 (second sheet) #3

Y EMBO J., Volume 6, number 2, published February 1987. 66,71
N. Takematsu, et al. "Expression of bacterial chloram-
phenicol acetyltransferase gene in tobacco plants
mediated by TMV-RNA" pp. 307-311. see entire article.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.